All In Biotech

Drug Trial Radar · NCT05466318

ChiCGB vs BEAM in High-risk or R/R Lymphomas

ChiCGB Versus BEAM With Autologous Stem-Cell Transplantation in High-risk Hodgkin and Non-Hodgkin Lymphoma - A Prospective, Multi-centered, Randomized Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jul 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 306 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

306

Planned (sponsor's estimate)

Start

Jul 1, 2022

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Sichuan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) plays a vital role in treating high-risked or relapsed/refractory lymphoma. Our previous study showed chidamide combined with cladribine, gemcitabine, and busulfan (ChiCGB) as conditioning therapy improved the survival of these patients. So we designed this trial to verify if ChiCGB were better than BCNU, etoposide, cytarabine, and melphalan (BEAM). Patients with diffuse large B cell or extra-nodal NK/T cell Lymphoma who consent to this study will be randomized into the trial group who receive ChiCGB or the control group whom receive BEAM. Patients will be followed for up to 2 years after the hematopoietic cell transplantation (HCT).

Conditions

  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, T-Cell

Interventions

  • ChidamideDrug

    30 mg oral twice weekly for 2 weeks

  • CladribineDrug

    6 mg/m2 intravenously once daily @ Day -7 \~ -3

  • GemcitabineDrug

    2500 mg/m2 intravenously @ Day -7, -3

  • BusulfanDrug

    3.2 mg/kg intravenously once daily @ Day -7 \~ -4

  • CarmustineDrug

    300 mg/m2 intravenously @ Day -8

  • EtoposideDrug

    200 mg/m2 intravenously once daily @ Day -7 \~ -4

  • CytarabineDrug

    400 mg/m2 intravenously once daily @ Day -7 \~ -4

  • MelphalanDrug

    140 mg/m2 intravenously @ Day -3

  • Autologous hematopoietic stem cell transplantProcedure

    autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: 2 years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • People's Hospital of Deyang City

    Deyang, Deyang, China · Not yet recruiting

  • Chengdu Third People's Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Chengdu First People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • PLA Western Theater Command General Hospital

    Chengdu, Sichuan, China · Recruiting

  • Dazhou Central Hospital

    Dazhou, Sichuan, China · Not yet recruiting

  • Southwest Medical University

    Luzhou, Sichuan, China · Recruiting

  • Central Hospital of Mianyang City

    Mianyang, Sichuan, China · Recruiting

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, Sichuan, China · Not yet recruiting

  • Zigong First People's Hospital

    Zigong, Sichuan, China · Recruiting

  • Guangyuan Central Hospital

    Guangyuan, Sihcuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.